ClinicalTrials.gg
CompletedNCT02975843Updated Jun 23, 2017

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

A Phase 1 interventional study of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium in Chronic Obstructive Pulmonary Disease and Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-23.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Beclomethasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
5th of 13
28 · median 24
Started
2016
with 1 other
Phase 1
3 of 13
none open now
Registered
11th of 13
by date
Lead sponsor
6 of 13
Chiesi Farmaceutici S.p.A.

Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 1, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide using a Gamma-scintigraphic technique after inhalation of a single dose of 99mTc radiolabelled CHF 5993 Administered via pMDI in healthy volunteers, asthmatic and COPD patients.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Asthma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written obtained prior to any study-related procedure
  2. (BMI) between 18 and 32 kg/m2
  3. Ability to understand the study procedures and the risks involved and ability to be trained to use the devices correctly at screening and pre-dose.
  4. Normal vital signs (Diastolic BP 60-90 mmHg, Systolic BP 90-140 mmHg or 90-150 if >45 yrs) at screening and pre-dose.
  5. 12-lead digitalised considered as normal: 60 ≤ heart rate ≤ 100 bpm, 120 ms ≤ PR ≤210 ms, QRS ≤ 120 ms, ≤ 450 ms (male) and ≤ 470 ms (female) at screening and pre-dose
  6. Males fulfilling one of the following criteria:

    1. Males with non-pregnant Women of (WOCBP) partners: they and/or their partner of childbearing potential must be willing to use a highly effective method in addition to the male condom from the signature of the informed consent and until 90 days after the follow-up visit. Subjects must not donate sperm during the study and for 90 days after the follow-up visit or
    2. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until 90 days after the follow-up visit. Subjects must not donate sperm during the study and for 90 days after the follow-up visit or
    3. Non-fertile male subjects (contraception is not required in this case) or
    4. Males with partner not of childbearing potential (contraception is not required in this case).
  7. WOCBP fulfilling one of the following criteria:

    1. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method with low user dependency from the signature of the informed consent and until 30 days after the follow-up visit or
    2. WOCBP with non-fertile male partners (contraception is not required in this case).
  8. Female patients of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile). Tubal ligation or partial surgical interventions are not acceptable. If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges)

    Additional Inclusion criteria for Healthy /volunteers and Asthmatic patients:

  9. Males and females aged 18-55
  10. Non- or Ex-smokers who smoked \< 5 pack years (pack-years = number of cigarette packs per day times the number of years) and stopped smoking > 1 year

    Additional Inclusion Criteria only for Healthy volunteers:

  11. Lung function within normal limits: ≥ 80% of predicted (according to the Global Lung Function Initiative, ERS Task Force Lung Function Reference Vales) and FEV1/FVC ratio > 0.70 at screening

    Additional Inclusion Criteria only for Asthmatic patients:

  12. Pre-bronchodilator 60% ≤ FEV1 ≤ 80% of predicted (according to the Global Lung Function Initiative, ERS Task Force Lung Function Reference Vales) and FEV1/FVC ratio > 0.70 at screening. If this criterion is not met at Screening, the test can be repeated once before Day -1.
  13. Positive reversibility test as defined by an increase in FEV1 ≥ 12% and at least 200 ml compared to the initial value 20-30 minutes after inhalation of 400 μg Salbutamol at screening. If this criterion is not met at Screening, the test can be repeated once before Day -1.

    Additional Inclusion Criteria only for patients:

  14. Males and females aged 40-75
  15. Current or ex- smokers (stopped smoking > 1 year ) minimum smoking history of 10 pack-years (packyears = number of cigarette packs per day times the number of years)
  16. 30% ≤ FEV1 \< 50% of predicted and FEV1/FVC \< 0.70 after inhalation of 400 μg Salbutamol. If this criterion is not met at Screening, the test can be repeated once before Day -1.

Exclusion criteria

Exclusion Criteria for all subjects:

  1. Pregnant or lactating women
  2. Documented history of drug abuse (within 12 months before screening) and/or positive urine drug test at screening and/or at treatment period
  3. History of to M3 Antagonists, β2-agonist, or any of the contained in any of the formulations used in the trial;
  4. Any abnormal laboratory value at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the result of the study according to the investigator's judgment
  5. Clinically relevant and uncontrolled hepatic, gastrointestinal, renal, genitourinary, endocrine, metabolic neurologic, or psychiatric disorder that may interfere with successful completion of this protocol
  6. Serology at the screening positive to HIV1 or HIV2 and positive results for Hepatitis which indicates acute or chronic (i.e. positive HB surface antigen HBsAg positive and/or positive HB core antibody anti-HBc) or (HCV antibody);
  7. Subjects with history of sustained and non-sustained cardiac arrhythmias ( demonstrated) and subjects with a family history of sudden cardiac death
  8. Subjects who have cardiovascular condition such as, but not limited to unstable ischemic heart disease, Class III/IV left ventricular failure, acute ischemic heart disease in the last year prior to study screening, which may impact the safety of the subject or the evaluation of the result of the study according to the investigator's judgment
  9. Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic agents"
  10. Significant blood loss ≥ 400 ml within 3 months prior screening and between screening and Day 1;
  11. Participation in another clinical trial with an drug in the previous 3 months before the administration of the study drug; a longer and more appropriate time could be considered by the principal investigator based on the elimination of the half-life and/or long term toxicity of the previous investigational drug;
  12. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.
  13. Unsuitable veins for repeated venipuncture
  14. Any not allowed concomitant medication

    Additional Exclusion criteria for Healthy volunteers and Asthmatic patients:

  15. Current use of any nicotine or nicotine replacement product

    Additional Exclusion criteria for Asthmatic and patients:

  16. Use of systemic steroids in the 4 weeks prior to screening and between screening and Day 1 (injectable depot steroids 6 weeks)
  17. Life-threatening/unstable respiratory status including upper or lower respiratory tract infection, within the previous 30 days before screening and between screening and Day 1
  18. Requirement for continuous oxygen therapy (supplemental oxygen not exceeding 2 l/min, at night only and/or during exercise is allowed)

    Additional Exclusion criteria only for asthmatic patients:

  19. Change in dose or type of any medications for asthma within 4 weeks prior to the screening visit
  20. Asthma exacerbation within the 4 weeks prior screening and between screening and Day 1
  21. History of COPD or any chronic respiratory disease other than Asthma

    Additional Exclusion criteria only for COPD patients:

  22. Change in dose or type of any medications for COPD within 4 weeks prior to the screening visit
  23. COPD exacerbation within the 4 weeks prior screening and between screening and Day 1
  24. History of asthma or any chronic respiratory disease other than COPD
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    CHF5993

    99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI

    Drug: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

Interventions

  • DrugBeclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

    Drug pages: Beclomethasone · Formoterol · Glycopyrrolate

    single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)

    Also known as: CHF5993 pMDI

06

What researchers measure

Primary outcomes

  1. Intrapulmonary Lung deposition expressed as % of nominal dose

    Calculated using the individual Gamma camera images

    Time frame: Immediately after dosing

Secondary outcomes

  1. Distribution of lung deposition

    Calculated using the individual Gamma camera images

    Time frame: Immediately after dosing

  2. Extrathoracic deposition

    Calculated using the individual Gamma camera images

    Time frame: Immediately after dosing

  3. Exhaled activity

    Calculated using the individual Gamma camera images

    Time frame: Immediately after dosing

  4. BDP/B17MP, Formoterol, and GB Area under curve (AUC) 0-t

    Calculated through plasma samples for PK evaluation

    Time frame: the area under the plasma concentration-time curve from 0 to the last quantifiable concentration. Over 24h

  5. BDP/B17MP, Formoterol, and GB Area under curve (AUC) 0-30min

    Calculated through plasma samples for PK evaluation

    Time frame: area under the plasma concentration-time curve from 0 to 30 min post-dose

  6. BDP/B17MP, Formoterol, and GB area under the curve (AUC) 0-∞

    Calculated through plasma samples for PK evaluation

    Time frame: area under the curve extrapolated to infinity over 24h

  7. BDP/B17MP, Formoterol, and GB Peak Plasma Concentration (Cmax)

    Calculated through plasma samples for PK evaluation

    Time frame: the value of the maximum plasma concentration will be obtained directly from the experimental data without interpolation. Over 24h

  8. BDP/B17MP, Formoterol, and GB tmax

    Calculated through plasma samples for PK evaluation

    Time frame: time of the maximum plasma concentration will be obtained directly from the experimental data without interpolation. Over 24h

  9. BDP/B17MP, Formoterol, and GB t½

    Calculated through plasma samples for PK evaluation

    Time frame: the terminal (apparent elimination) half-life over 24h

  10. lung function assessment

    Calculated using spirometry

    Time frame: Over 24 h post dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2017, 4 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 4 months is close to that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2016
First posted
Nov 29, 2016
StartActual
Nov 21, 2016
Primary completionActual
Mar 21, 2017
CompletionActual
Apr 11, 2017
Last update
Jun 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02975843
Responsible party
Sponsor
First posted
Nov 29, 2016
Start date
Nov 21, 2016
Primary completion
Mar 21, 2017
Completion
Apr 11, 2017
Last update
Jun 23, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Formoterol · Glycopyrrolate

Start the discussion